Pioneers of transplantation John Gurdon
Interview with Sir John Gurdon, developmental biologist and forefather of stem cell medicine. The footage, produced by Figment Productions, formed part of an exhibition organised by the MRC...
By: Medical Research Council
Stem Cell Therapy | stem cell mobilization gcsf
http://www.arthritistreatmentcenter.com Another breakthrough in stem cell science and we have lab rats to thank for it next Osteoarthritis in rats responds to stem cell mobilization therapy...
By: Nathan Wei
See the article here:
Stem Cell Therapy | stem cell mobilization gcsf - Video
JANUARY 2014 State of the Industry Briefing at EBD's Biotech Showcase Jan 13. San Francisco, CA EBD's Biotech Showcase: Regenerative Medicine Industry Track Jan 13-15. San Francisco, CA ECI's Conference on Scale-Up and Manufacturing of Cell-Based Therapies Jan 6-9. San Diego, CA International Conference on Cell Therapy for Cardiovascular Disease Jan 22-24. New York, NY Phacilitate's Cell and Gene Therapy Forum Jan 27-29. Washington, DC FEBRUARY 2014 RRY's New York Stem Cell Summit Feb 18. New York, NY STEMSO's International Stem Cell Society Conference Feb 19-22. Freeport, Grand Bahama BMT Tandem Meetings Feb 26-Mar.Grapevine (Dallas), TX MARCH 2014 Danish Stem Cell Symposium Mar 7-8. Hillerd, Denmark ISBioTech Spring Mtg - Cellular Therapies Track Mar 10-12. Washington, DC AAT's Advanced Therapies Summit Mar 12-13. Turin, Italy ISSCR/SBE International Conference on Stem Cell Engineering Mar 16-19. Coronado, CA Congress on Stem Cell and Cell Therapies Mar 2023. Koceli, Turkey FDA and the Changing Paradigm for HCT/P Regulation Mar 24-26. Bethesda, MD BIRAXs' UK-Israel Regenerative Medicine Conference Mar 25-26. Haifa, Israel ARM's RegenMed Investor Day Mar 26. New York, NY. Regenerative Medicine Workshop at Hilton Head Mar 26-29 . Hilton Head, SC Cancer Immunotherapy: A Long-Awaited Reality Mar 27. NYC, NY. FDA Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Public Mar 31. Silver Spring, MD.
APRIL 2014 Select Biosciences' Clinical Translation of Stem Cells Apr 21-22. Palm Springs, AZ ISCT Annual Meeting Apr 23-26. Paris, France GTCBio's Stem Cell Summit Apr 23-25. Boston, MA ARMs Annual Dinner & Legislative Fly-In Apr 28-9. Washington, DC.
MAY 2014 GeneExpression Systems' Stem Cells and Cell Signaling Mtg on Assays to Regenerative Medicine, Tissue Engineering and Therapeutics May 5-6. Waltham-Boston, MA Regenerative Medicine Foundation Symposium May 5-7. San Francisco, CA CHIsAdoptive T Cell Therapy:New Targets and Strategies for Immune Driven Diseases (part of the Tenth Annual PEGS: the essential protein engineering summit) May 7-8. Boston, MA ASGCT - American Society of Gene and Cell Therapy Mtg May 21-24. Washington, DC Terrapinn's World Stem Cells and Regenerative Medicine Congress May 20-22. London, UK JUNE 2014 PDA Europe: Advanced Therapy Medicinal Products Jun 3-4. Madrid, Spain The Orthobiologic Institute's PRP and Regenerative Medicine Symposium Jun 6-7. Los Angeles, CA Israstem Jun 10-11. Ramat, Gan. Israel TERMIS EU Mtg Jun 10-14. Genova, Italy ISSCR - International Society for Stem Cell Research Mtg Jun 18-21. Vancouver, BC, Canada Cell Tracking Symposium June 20. London, ON
BIO International Convention(with BPI BioProcess Theater) Jun 23-26. San Diego, CA ARM Networking Reception @BIO June 24. San Diego, CA OMIC'sCell Science and Stem Cell Research Jun 24-26. Valencia, Spain JULY 2014 The Business of Regenerative Medicine: New Therapies, New Models July 14-16. Toronto, ON Regenerative Medicine Essentials: The Fundamentals to the Future. July 21-25.Winston-Salem, NC
AUGUST 2014 CHI'sCell Therapy Bioproduction (part of the Bioprocessing Summit) Aug 18-22. Boston, MA Rejuvenation Biotechnology: Emerging Regenerative Medicine Solutions for the Diseases of Aging conference Aug 21-23. Santa Clara, CA.
SEPTEMBER 2014 Terrapinn's Stem Cells USA and Regenerative Medicine Congress Sep 15-16. Boston, MA IBC's Cell Therapy Bioprocessing Sep 15-16. Arlington, VA TERMIS Asia Pacific Mtg Sep 24-17. Daegu, S. Korea
OCTOBER 2014 Cancer Immunotherapy 2014 Oct. 6. New York City, NY ARM's Stem Cell Meeting on the Mesa Oct 7-9. La Jolla, CA Fraunhofer Life Science Symposium"Medicinal Stem Cell Products Oct 9-10. Leipzig, Germany Translational Regenerative Medicine Congress Oct 21-22. Leipzig, Germany CCRM-SCN Till and McCulloch Meetings Oct 27-29. Ottawa, ON, Canada OMICS' International Conference and Exhibition on Cell and Gene Therapy Oct 27-29. Las Vegas, NV
NOVEMBER 2014 ISSCR/SSCS Global Controls in Stem Cells Nov 5-7, 2014. Singapore Society for Immunotherapy of Cancer Annual Meeting Nov 6-9. National Harbor, MD International Conference on Stem Cells and Cancer (ICSCC-2014): Proliferation, Differentiation and Apoptosis Nov 8-10. New Delhi, India IFATS Annual Mtg Nov 13-16. Amsterdam, NL BIT's World Congress of Regenerative Medicine & Stem Cells (RMSC2014) Nov 13-16.Haikou, China Commercial Translation of Regenerative Medicine Nov/Dec ??. London, UK DECEMBER 2014 Cell Therapy Manufacturing Dec 3-4. Brussels, Belgium World Stem Cell Summit Dec 3-5. San Antonio, TX TERMIS Americas Mtg Dec 13-16. Washington, DC If I've missed an event you'd like to see added, please email me at lbuckler [at] celltherapygroup [dot] com.
Go here to read the rest:
Cell Therapy Blog: Cell Therapy Conferences 2014
Stem Cell Treatment for Stroke
Research Protocol registered with Stem Cell Registry of the Ministry of Health, Malaysia:
Presented at the 3rd International Association of Neurorestoratology Annual Congress (IANRAC III), Beijing 23-25 April 2010: Foo-Chiang Lee (Malaysia): Multicentre phase II study assessing the safety and efficacy of intracerebral autologous mesenchymal stem cells in chronic stroke patients http://www.ianr.org.cn/English/new.asp?id=1226
Forthcoming presentation at 8th Asian Congress of Neurological Surgeons, Kuala Lumpur, 20-21 November 2010:
Dr. Chee-Pin CHEE, Foo-Chiang LEE, Dr. Moon-Keen LEE, Sze-Piaw Chin, Zaliha Omar. Autologous bone marrow stem cell transplantation for stroke patients: an initial report.
ABSTRACT OF PAPER presented at IANRAC III Beijing
MULTICENTRE PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRACEREBRAL AUTOLOGOUS MESENCHYMAL STEM CELLS IN CHRONIC STROKE PATIENTS.
Dr. Foo-Chiang LEE 1, Dr. Chee-Pin CHEE 2, Dr. Moon-Keen LEE3, Assoc Prof Sze-Piaw Chin4 and Dr. Zaliha Omar5
Read the rest here:
Stem Cell Treatment in Malaysia | Advanced Clinical ...
Adult stem cells can change the healthcare landscape
A recent Colorado political advertisement highlighting a candidates stance on stem cell research shows the issue is still at the forefront of public consciousness. Part of what makes stem cell research such a hot button issue is the number of persistent myths that propagate many of the heated emotions surrounding the topic.
Much of the stem cell controversy comes from the fact many people only know of embryonic stem cells, which are generated from fertilized, frozen eggs at in-vitro fertilization centers. These are not the only type of stem cells. Other types include umbilical cord blood and adult stem cells.
Umbilical cord blood is extracted from birth and preserved for the future benefit of the child. While this type of stem cell technique is safe and it is becoming commonplace to store the cells, there is currently no way to utilize these cells beyond compassionate care cases which are few and far between. However, adult stem cells are currently in clinical use today and are easily and safely harvested from the patients fat and bone marrow reserves. The adult stem cells can be utilized for a variety of treatment options, which include joint, ligament and tendon injuries, back pain, and autoimmune diseases.
Polls indicate a shifting paradigm in how people view stem cell use and research. A Pew Research survey conducted in 2013 revealed only 16 percent believed non-embryonic stem cell research was immoral. Pope Emeritus Benedict XVI recently gave his approval on adult stem cell research, I pray that your commitment to adult stem cell research will bring great blessings for the future of man and genuine enrichment to his culture.
Those with an understanding of adult stem cells know there is no controversy as they do not require the harming of an embryo. While progress in the realm of public opinion is being made, regulatory and administrative difficulties are still hampering medical innovation according to some healthcare experts.
Adult stem cells hold great promise for the future of medicine because of their potential to improve cartilage health, repair lumbar discs, and slow progression of autoimmune diseases. The ability to utilize stem cells from ones own body to safely and naturally heal itself from many different ailments is beginning to revolutionize healthcare.
With more public support and cooperative regulatory policies, adult stem cells have the potential to forever change the healthcare landscape as profoundly as the mark antibiotics made on medicine.
Dr. Scott Brandt
ThriveMD Aspen
The rest is here:
Letter: Adult stem cells can change the healthcare landscape
CHENNAI: Doctors at a private hospital in the city gave a new lease of life to a 7-year-old Iraqi girl, Nourl Al Zahara, who suffered from a heart problem, dilated cardiomyopathy. The team of surgeons treated her condition through stem cell transplant.
Zahara, the only child of Salem, a botany teacher and Raza, a lawyer at Baghdad, began to experience tiredness and problems with breathing when she was merely 6-months-old. Despite taking her to several doctors in Baghdad, her parents could not find a cure for the girl who was later brought to Frontier Lifeline Hospital in Chennai.
Doctors who ran tests on her found that the child has been suffering from dilated cardiomyopathy, where the heart muscle becomes enlarged and gets damaged. Considering her age, the surgical team decided to treat her condition with a stem cell transplant. In this treatment, stem cells are separated and multiplied from the patient's bone marrow and is then injected into the patient's heart.
Speaking about the treatment, DDr K M Cherian of Frontier Lifeline Hospital said, "Stem cell therapy gives the heart a chance to regenerate. As the heart does not have the capacity to heal by itself, this therapy helps in the process."
The main intention of the stem cell treatment is to ensure quality life for heart patients from the first stage of medication until the final stage of treatment, the doctor added. Following the transplant, the child's condition began to stabilize and she showed signs of recovery. "She is healthy now and is even looking forward to go to school," said Dr Cherian.
Stay updated on the go with The Times of Indias mobile apps. Click here to download it for your device.
Visit link:
Chennai doctors give new lease of life to Iraq girl
Irelands first human stem cell trial using lab-grown cells is due to get underway in Galway in the new year following approval from the medicines watchdog.
The trial will involve extracting adult mesenchymal stem cells (MSC) from the bone marrow of patients with a condition known as critical limb ischemia (CLI) a severe blockage of the arteries resulting in marked reduction in blood flow to the extremities.
Reduction in blood flow to the legs puts patients at risk of gangrene, ulceration, and amputation, and the Galway trial will look at the use of MSCs to grow new stems cells which will then be injected back into the patients leg with the hope of growing new blood cells and improving circulation.
The harvested stem cells will be grown to much greater quantities in a highly specialised lab before being injected back into the patients leg.
Tim OBrien, director of the Galway-based Regenerative Medicine Institute, said their research was focused on whether MSC therapy could improve blood flow to the legs in patients with CLI a condition common in diabetics and therefore avoid the need for amputation. The trial is aimed predominantly at testing the safety and feasibility of what is very much an experimental therapy, Prof OBrien said.
We will be doing a dose escalation study, with some patients given a small dose, others a medium dose and the remainder a high dose, he said. We want to try and establish how many cells do you need to give a patient.
The study, the first in humans in Ireland, will be a year-long study involving nine patients. Prof OBrien said they would not be advertising for participants, but rather would let clinicians know and await referrals of suitable patients.
In the meantime, they would be preparing the custom-built facility where the cells are grown, at the Centre for Cell Manufacturing Ireland in NUI Galway, the first such facility in Ireland to receive a licence from the Health Products Regulatory Authority.
Prof OBrien said MSCs have a lot of properties that may make them useful in treating a wide variety of disease because of their reparative and regenerative qualities.
Prof OBrien delivered a talk yesterday on the Therapeutic Potential of MSCs in Diabetic Complications on the second day of a two-day international stem cell conference at NUI Galway.
Read the rest here:
Lab-grown stem cell trial gets green light
DALLAS, October 29, 2014 /PRNewswire/ --
According to the new market research report The"Cell Expansion Marketby Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative Medicine, Clinical Diagnostics), End User (Hospital, Biotechnology, Cell Bank) - Forecast to 2019", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Cell Expansion Market along with the estimates and forecasts of the revenue and share analysis.
Browse 149 Market Data Tables and 56 Figures spread through 224 Pages and in-depth TOC on"Cell Expansion Market"
http://www.marketsandmarkets.com/Market-Reports/cell-expansion-market-194978883.html
Early buyers will receive 10% customization on this report.
The global Cell Expansion Market is expected to reach $14.8 Billion by 2019 from $6.0 Billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019.
The report segments this market on the basis of product, cell type, application, and end user. Among various applications, the regenerative medicines is expected to account for the largest share in 2014 and is expected to account for the fastest-growing segment in the cell expansion market, owing to technological advancement due to which new products are being launched in the market. Furthermore, rising investments by companies and government for research is another major reason for the growth of this market.
Based on geography, the global Cell Expansion Market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2014. The large share of this region can be attributed to various factors including increasing government support for cancer and stem cell research and increasing prevalence of chronic diseases in this region.
Further Inquiry:http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=194978883
Prominent players in the Cell Expansion Market are Becton, Dickinson and Company (U.S.), Corning Incorporated (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K.), Merck Millipore (U.S.), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Sigma-Aldrich Corporation (U.S.), Terumo BCT (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
View post:
Cell Expansion Market Worth $14.8 Billion by 2019
Special Arrangement Nourl Al Zahara suffered from cardiomyopathy, a condition in which the heart muscles get enlarged and weak.
A seven-year-old girl from Iraq underwent stem cell treatment for a heart ailment at Frontier Lifeline Hospital, recently.
The child, Nourl Al Zahara from Baghdad, is the only child of Salem, a botany teacher, and Raza, a lawyer. She was diagnosed with dilated cardiomyopathy, a condition in which the heart muscles get enlarged and weak. When she was six months old, she had trouble breathing, and when she began walking, would get tired easily. Her skeletal muscles were also weak.
Stem cell treatment was chosen, a release from the hospital said, as doctors wanted to give Nourls heart a chance to regenerate and ensure her quality of her life was not compromised.
As the heart does not have the capacity to heal by itself, stem cell therapy helps in the process. The treatment was successful and the child is now healthy and looking forward to going to school, said CEO and chairman of the hospital K.M. Cherian, according to the release.
The hospital has permission and approval from the Indian Council of Medical Research for stem cell treatment for heart diseases. Over 100 children have benefited from stem cell implantations at the hospital, the release said.
See the original post here:
Iraqi child gets stem cell treatment in city
The thorny and unresolved question of whether life itself can be patented may come again before the U.S. Supreme Court, if it accepts a motion filed Friday by Santa Monica-based Consumer Watchdog. (H/T to David Jensen's California Stem Cell Report.)
The issue isn't a new one either for the consumer group or the court. Consumer Watchdog launched its challenge of a patent on human stem cells issued to the Wisconsin Alumni Research Foundation, or WARF, in 2006. Since then the battle has been waged before the U.S. Patent Office, which overturned the patent then reinstated a narrower version; and the U.S. Court of Appeals for the Federal Circuit, which hears patent appeals.
The group has challenged the patent on two grounds: first, that the work covered wasn't novel or original, and second, that the Supreme Court has ruled that a "product of nature" can't be patented.
That ruling came in 2013, in a case involving laboratory-isolated DNA. Even then, however, the court left the door open for patents of some biological products, notably "composite DNA," which is synthetically created in the lab.
The court's attempt to split hairs, so to speak, reflects its discomfort with the very question of where to draw the line on what sort of organisms can be patented.
As it happens, that question was placed before the court only indirectly by the Consumer Watchdog motion. The immediate issue is whether the organization had legal standing to appeal the patent office's ruling in the first place. The appeals court threw out its appeal last year on the grounds that it hadn't been injured by WARF's patent, normally a prerequisite for bringing a lawsuit in federal court.
Consumer Watchdog's lawyer, Daniel Ravicher at the Public Patent Foundation, says patent law explicitly allows parties that challenge a patent to appeal an adverse ruling to a higher court. He speculates that the appeals court raised the standing issue on its own last year because it was inclined to uphold the patent, and feared being overturned by the Supreme Court.
"This case is almost identical to the genes case," Ravicher says. His goal is for the Supreme Court to accept its motion and order the appeals court to reconsider the stem cell patent on its merits. If that happens, the underlying issue of the patentability of life is almost certain to land back in the Supreme Court's lap.
All this is happening, researchers say, because WARF made exceptionally broad claims for its patent rights and exercised them very aggressively. This is, in fact, WARF's business; the nonprofit foundation was formed in the 1920s to exploit a patent issued to a University of Wisconsin professor on fortifying food with vitamin D, which it promptly licensed to Quaker Oats. By 1930, the deal was producing $1,000 a day. WARF also owns the rights to the drug Warfarin, which is named after the foundation.
A stem cell patent was originally issued to Wisconsin's James Thomson in 1995 (two more followed later), covering his extraction of stem cells from human embryos. WARF at first maintained that the patents covered the use of any human embryonic stem cells, and even products eventually produced by research using them.
Read the original:
Can scientists patent life? The question returns to the Supreme Court